Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656630 · ClinicalTrials.gov registry record · Phase 2
Medication Development in Alcoholism: Acamprosate Versus Naltrexone
A Phase 2 study, sponsored by The Scripps Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00656630: Completed Phase 2 study, sponsored by The Scripps Research Institute.
NCT00656630 is a Phase 2 study that has completed, run by The Scripps Research Institute. The registered enrollment target is 68 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00656630, a Phase 2 study, has completed, sponsored by The Scripps Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.
Primary Outcome
The four Visual Analog Scale questions assess domains of alcohol craving: the intention to drink, loss of control, relief craving, and urge intensity. The scale ranges from 0-20 where a zero indicates no craving and 20 indicates severe craving; thus, a higher score indicates a worse outcome. Total is a summation of the four subscales (i.e. Strength, Intent, Impulse, Relief) and ranges in value from 0-80 with higher scores indicative of a worse outcome.
Interventions
- DRUG Placebo
- DRUG Acamprosate
- DRUG Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00656630 record still lists
NCT00656630 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00656630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00656630 about?
NCT00656630 is a clinical study titled "Medication Development in Alcoholism: Acamprosate Versus Naltrexone". The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.
What is the current status of trial NCT00656630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2007-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00656630?
The interventions under investigation include: Placebo (DRUG), Acamprosate (DRUG), Naltrexone (DRUG).
Who is sponsoring clinical trial NCT00656630?
This trial is sponsored by The Scripps Research Institute, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00656630's enrollment target sits among peer trials
68 967th of 2000 higher than 1,027 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia